Nuvectis Pharma (NVCT) Interest & Investment Income (2022 - 2026)
Nuvectis Pharma (NVCT) reported Interest & Investment Income of $210000.0 for Q1 2026, down 11.02% on a YoY basis from $236000.0 in Q1 2025, and down 30.69% sequentially from $303000.0 in Q4 2025.
Nuvectis Pharma (NVCT) Interest & Investment Income (2022 - 2026) Analysis & Trends
Nuvectis Pharma (NVCT) has 5 years of Interest & Investment Income data on file, last reported at $210000.0 in Q1 2026.
- For the quarter ending Q1 2026, Interest & Investment Income fell 11.02% year-over-year to $210000.0; the trailing twelve-month figure through Mar 2026 stood at $1.1 million (up 28.9% YoY), and the FY2025 full-year result was $1.1 million, up 33.65% from the prior year.
- Interest & Investment Income slipped to $210000.0 in Q1 2026, from $303000.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $332000.0 in Q3 2025 to a low of $2000.0 in Q1 2022.
- A 5-year average of $175000.0 and a median of $210000.0 in 2026 frame the typical range for Interest & Investment Income.
- Across the five-year window, Interest & Investment Income jumped 2500.0% in 2023 and dropped 25.63% in 2024, its largest moves.
- Tracing NVCT's Interest & Investment Income over 5 years: stood at $82000.0 in 2022, then surged by 197.56% to $244000.0 in 2023, then retreated by 17.62% to $201000.0 in 2024, then jumped by 50.75% to $303000.0 in 2025, then sank by 30.69% to $210000.0 in 2026.
- Business Quant data shows NVCT's Interest & Investment Income at $210000.0 in Q1 2026, $303000.0 in Q4 2025, and $332000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 27.66 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 114.80 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -65.80 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 48.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 19.51 Mn |
| 10 | Nuvectis Pharma | 457.99 Mn | 457.99 Mn | - | 210,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 210,000.00 |
| Dec 31, 2025 | 303,000.00 |
| Sep 30, 2025 | 332,000.00 |
| Jun 30, 2025 | 261,000.00 |
| Mar 31, 2025 | 236,000.00 |
| Dec 31, 2024 | 201,000.00 |
| Sep 30, 2024 | 206,000.00 |
| Jun 30, 2024 | 215,000.00 |
| Mar 31, 2024 | 225,000.00 |
| Dec 31, 2023 | 244,000.00 |
| Sep 30, 2023 | 277,000.00 |
| Jun 30, 2023 | 64,000.00 |
| Mar 31, 2023 | 52,000.00 |
| Dec 31, 2022 | 82,000.00 |
| Sep 30, 2022 | 61,000.00 |
| Jun 30, 2022 | 4,000.00 |
| Mar 31, 2022 | 2,000.00 |